#akynzeo

In this article, we will discuss AKYNZEO and Warfarin. So, let’s get started. Although it was predicted that co-administration of intravenous AKYNZEO with warfarin would not substantially increase the systemic exposure to S-warfarin (CYP2C9 substrate), the activeenantiomer, the effects of AKYNZEO for injection and AKYNZEO capsules on INR andprothrombin time have not been studied. Monitor INR and…

In this article, we will discuss AKYNZEO and Hypersensitivity. So, let’s get started. Hypersensitivity Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with palonosetron, one of the components of AKYNZEO, with or without known hypersensitivity to other 5-HT3 receptor antagonists.

Akynzeo (Dosage Forms and Strength)

In this article, we will discuss Akynzeo (Dosage Forms and Strength). So, let’s get started. Akynzeo (Dosage Forms and Strength)Capsules: 300 mg netupitant/0.5 mg palonosetron in a hard gelatin capsule with white body and caramel cap with “HE1” printed on the body.For Injection: 235 mg fosnetupitant/0.25 mg palonosetron white to off-white lyophilized powder in single-dose vial for reconstitution.

AKYNZEO (Mechanism of Action)

In this article, we will discuss AKYNZEO (Mechanism of Action). So, let’s get started. Mechanism of Action Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors. Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of…